Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ImExHS Limited ( (AU:IME) ) has issued an announcement.
IMEXHS Limited reported a Q1 FY25 revenue of $7.1 million, marking a 1% increase compared to the previous corresponding period, with an 8% rise excluding a one-off sale. The company also saw a 16% growth in Annualized Recurring Revenue (ARR), reaching $31.4 million. The quarter highlighted the commercial launch of Aquila+, their next-generation radiology platform, now operational at eight sites, alongside securing new software contracts and a significant contract extension. The company raised $2.5 million through capital raising initiatives to support growth, with further fundraising efforts underway. These developments indicate a strategic focus on expanding their market presence and enhancing profitability in radiology services.
More about ImExHS Limited
IMEXHS Limited is an innovative provider of cloud-based medical imaging software and radiology services, operating across 18 countries. The company focuses on delivering advanced radiology platforms and services, leveraging AI-enabled software to enhance speed, accuracy, and cost-effectiveness in medical imaging.
YTD Price Performance: -11.84%
Average Trading Volume: 27,432
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$16.9M
For detailed information about IME stock, go to TipRanks’ Stock Analysis page.